Abstract:BackgroundIncreased plaque vulnerability and higher lipid variability are causes of adverse cardiovascular events. Despite a close association between glucose and lipid metabolisms, the influence of elevated glycated hemoglobin A1c (HbA1c) on plaque vulnerability and lipid variability remains unclear.MethodsAmong subjects undergoing percutaneous coronary intervention (PCI) from 2009 through 2019, 366 patients received intravascular optical coherence tomography (OCT) assessment and 4,445 patients underwent the scheduled follow-ups within 1 year after PCI. Vulnerability features of culprit vessels were analyzed by OCT examination, including the assessment of lipid, macrophage, calcium, and minimal fibrous cap thickness (FCT). Visit-to-visit lipid variability was determined by different definitions including standard deviation (SD), coefficient of variation (CV), and variability independent of the mean (VIM). Multivariable linear regression analysis was used to verify the influence of HbA1c on plaque vulnerability features and lipid variability. Exploratory analyses were also performed in non-diabetic patients.ResultsAmong enrolled subjects, the pre-procedure HbA1c was 5.90 ± 1.31%, and the average follow-up HbA1c was 5.98 ± 1.16%. By OCT assessment, multivariable linear regression analyses demonstrated that patients with elevated HbA1c had a thinner minimal FCT (β = −6.985, P = 0.048), greater lipid index (LI) (β = 226.299, P = 0.005), and higher macrophage index (β = 54.526, P = 0.045). Even in non-diabetic patients, elevated HbA1c also linearly decreased minimal FCT (β = −14.011, P = 0.036), increased LI (β = 290.048, P = 0.041) and macrophage index (β = 120.029, P = 0.048). Subsequently, scheduled follow-ups were performed during 1-year following PCI. Multivariable linear regression analyses proved that elevated average follow-up HbA1c levels increased the VIM of lipid profiles, including low-density lipoprotein cholesterol (β = 2.594, P < 0.001), high-density lipoprotein cholesterol (β = 0.461, P = 0.044), non-high-density lipoprotein cholesterol (β = 1.473, P < 0.001), total cholesterol (β = 0.947, P < 0.001), and triglyceride (β = 4.217, P < 0.001). The result was consistent in non-diabetic patients and was verified when SD and CV were used to estimate variability.ConclusionIn patients undergoing elective PCI, elevated HbA1c increases the atherosclerotic plaque vulnerability and the visit-to-visit variability of lipid profiles, which is consistent in non-diabetic patients.

Visit-to-visit variability of lipid and cardiovascular events in patients with familial hypercholesterolemia

Hemoglobin A1c Levels Affect Visit-to-visit Variability of Lipid Profiles in Patients Undergoing Elective Percutaneous Coronary Intervention: A Retrospective Study

Association Between Visit-to-visit Lipid Variability and Risk of Ischemic Heart Disease: a Cohort Study in China

VARIABILITY IN PLASMA LIPIDS BETWEEN INTENSIVE STATINS THERAPY AND CONVENTIONAL DOSE STATINS COMBINED WITH EZETIMIBE THERAPY IN PATIENTS WITH CORONARY ATHEROSCLEROSIS DISEASE

Variability in Non-HDL-C and Lp(a) Affect the Neutrophil to Lymphocyte Ratio in Patients Undergoing Elective Percutaneous Coronary Intervention

ELEVATION OF HEMOGLOBIN A1C INCREASE THE ATHEROSCLEROTIC PLAQUE VULNERABILITY AND THE VISIT-TO-VISIT VARIABILITY OF LIPID PROFILES IN PATIENTS WHO UNDERWENT ELECTIVE PERCUTANEOUS CORONARY INTERVENTION

Visit-to-visit Variability in LDL-cholesterol is Associated with Adverse Events in Non-Obstructive Coronary Artery Disease

Prognostic Significance of Visit-to-visit Variability, and Maximum and Minimum LDL Cholesterol in Diabetes Mellitus

Familial Hypercholesterolemia Genetic Variations and Long-Term Cardiovascular Outcomes in Patients with Hypercholesterolemia Who Underwent Coronary Angiography

Variability of the Plasma Lipidome and Subclinical Coronary Atherosclerosis

Lipid Variability and Risk of Cardiovascular Diseases and All-Cause Mortality: A Systematic Review and Meta-Analysis of Cohort Studies

Prevalence and prognosis of molecularly defined familial hypercholesterolemia in patients with acute coronary syndrome

Risk of Recurrent Coronary Events in Patients With Familial Hypercholesterolemia; A 10-Years Prospective Study

Comprehensive Assessment of Lipid Markers in Cardiovascular Events Prediction

Relations of physical signs to genotype, lipid and inflammatory markers, coronary stenosis or calcification, and outcomes in patients with heterozygous familial hypercholesterolemia

Variability in Lipid Profiles During Young Adulthood and the Risk of Coronary Artery Calcium Incidence in Midlife: Insights From the CARDIA Study

Synergistic effect of the commonest residual risk factors, remnant cholesterol, lipoprotein(a), and inflammation, on prognosis of statin-treated patients with chronic coronary syndrome

Clinical Impact of Lipoprotein (a) and Cumulative Low-Density Lipoprotein Cholesterol Exposure on Coronary Artery Disease in Patients with Heterozygous Familial Hypercholesterolemia

Baseline levels of serum high sensitivity C reactive protein and lipids in predicting the residual risk of cardiovascular events in Chinese population with stable coronary artery disease: a prospective cohort study

Lipoprotein(a), family history of cardiovascular disease, and incidence of heart failure

Elevated Lipoprotein(a) and Genetic Polymorphisms in the LPA Gene May Predict Cardiovascular Events